Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy

Article ID	Journal	Published Year	Pages	File Type
8229783	International Journal of Radiation OncologyBiologyPhysics	2011	6 Pages	PDF

Abstract

These results suggest that ERCC1 expression might be a useful predictive marker in patients with locally advanced nasopharyngeal cancer who are under consideration for cisplatin-based concurrent chemoradiotherapy.

Keywords

excision repair cross-complementation group 1 Nasopharyngeal cancer cisplatin Predictive factor Concurrent chemoradiotherapy ERCC1

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy

Authors

Jong-Mu M.D., Myung-Ju M.D., Ph.D., Min Jae M.D., Hui-Young M.D., Jin Seok M.D., Ph.D., Seungkoo M.D., Gu M.D., Joungho M.D., Ph.D., Young-Ik M.D., Ph.D., Chung-Hwan M.D., Ph.D., Yong Chan M.D., Ph.D., Keunchil M.D., Ph.D.,